Oncology

This study explores the causes of emotionally adverse patient experiences in cancer care and presents a taxonomy for analyzing free-text patient data.

Patients with cancer who receive high doses of bisphosphonates, used to treat bone cancer, can experience jaw damage. New preclinical research published in Bone Science Direct could prevent these patients from experiencing this loss of jawbone tissue after routine oral surgery.

Patients who adhere to a CancerIQ cancer prevention plan, or cancer survivorship plan, are more likely to catch a cancer before it grows beyond 1 centimeter, says Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.

An artificial intelligence system can digest what would take a person 29 hours to read in about 30 seconds, so everything is right in front of providers at the point of care, says Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.

During a session at Asembia’s 15th annual Specialty Pharmacy Summit, Greg Simon, president, Biden Cancer Initiative, outlined commitments that came out of the Cancer Moonshot, the work of the Biden Cancer Initiative, and ongoing challenges that patients with cancer face.

New technologies are enabling pharmacists to play a bigger role in managing overall care delivery and the cost of care for patients with cancer, explained Matt Farber, MA, senior director of Patient Care and Advocacy for Walgreens.

Stephen Grubbs, MD, vice president of clinical affairs at the American Society of Clinical Oncology, explains what stakeholders can expect from the new updates to the Patient-Centered Oncology Payment (PCOP) model, as well as some key differences between PCOP and the Oncology Care Model.

Blase Polite, MD, associate professor of medicine and the executive director for accountable care at the University of Chicago, discusses why he chose to focus on the state of the Oncology Care Model at the April 25 meeting of the Institute for Value-Based Medicine.

The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovation in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at Asembia's 15th annual Specialty Pharmacy Summit, held April 29 to May 2 in Las Vegas.

Payers, providers, and other stakeholders have to come together to figure out how to make a better patient member experience for those who are fighting cancer, said Bryan Loy, MD, physician lead, oncology, laboratory, and personalized medicine, Humana.

The standard treatment isn’t always right for everyone, and part of a social worker’s job as a member of the care team is to understand the patient’s goals and what treatment is the right fit for them, said Abra Kelson, MSW, LSWA-IC, medical social work supervisor, Northwest Medical Specialties.

CancerIQ has automated a lot of time-consuming steps to allow operationally efficient community cancer centers a way of offering genetic screening in a profitable manner, said Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.

Implementing new payment models is really complicated, and the private sector is not doing as much as the public sector, said Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc.

Taking care of a patient in the shift to value-based care means utilizing care managers to answer questions when the physician isn’t available, says Beth Wittmer, RN, OCN, manager of care management at Florida Cancer Specialists and Research Institute.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

With all the regulatory changes that CMS and HHS are rolling out, community oncology practices are facing significant changes in how they take care of patients, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.

The core of the work that care coordinators do is done behind the scenes so that all of the core information is in the chart when the doctor is meeting with the patient, said Jessa Dunivan, patient services manager, Northwest Medical Specialties.

This week, the top managed care news included a study demonstrating that diabetes drug canagliflozin cuts the risk of renal failure and death; the FDA approving the first targeted therapy for metastatic bladder cancer; approximately half of all cancer deaths are attributable to modifiable risk factors.

Using oncology care pathways and treatment pathways has helped practices use evidence-based data to facilitate them to be sure they are using the right drug for the right patient at the right time, said Ray Page, DO, PhD, president and director of research at The Center for Cancer and Blood Disorders.

https://www.pharmacytimes.org/on-demand/the-era-of-parp-inhibition-in-cancer-management-patient-selection-and-deciding-when-to-use-in-treatment-enduring

AJMCtv® interviews let you catch up with experts on what’s new and important about changes in healthcare. The interviews provide insights from key decision makers-from the clinician to the health plan leader to the regulator. When every minute in your day matters, AJMCtv® interviews keep you informed. You can access the video clips at www.ajmc.com/interviews.

Managed care updates.

Regulatory and clinical updates.

When breast cancer spreads, it often goes to the bones, and new research has found that exposure to dim light at night may contribute to this spread. Results from the animal study were presented at ENDO 2019, the annual meeting of the Endocrine Society.

There are disparities in access to innovative therapies and entries into clinical trials, but FDA's recent proposed guidance could help close gaps, said John W. Sweetenham, MD, senior director of clinical affairs and executive medical director, Huntsman Cancer Institute at the University of Utah.